| Patient | Billie Holiday |
|---|---|
| Date of birth | 1915-04-07 |
| Identifiers | MRN HR-ML010-SYN-TD; SSN (made up) 000-10-4472 |
| Document date | 1948-08-31 |
| Author | Constance Mayfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Ms. Holiday is a 33-year-old singer with a severe opioid use disorder on buprenorphine and a moderate alcohol use disorder on acamprosate, who comes for her yearly preventive visit six weeks after her three-month review. Since that visit, when the recovery plan was adjusted after a brief return to use on tour, she has taken buprenorphine every day without a gap and has used no heroin or other opioids. The pharmacy now fills her prescription before each tour, and she carries a travel letter. She drinks one or two drinks on some performance nights and none on most other days. She still carries naloxone and fentanyl test strips. She meets her counselor weekly and her peer recovery coach by phone. Her mood is better, and her PHQ-9 today is 6. She has no new concerns. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 33 |
| Opioid use | None since the return to use before the three-month visit; buprenorphine daily without gaps |
| Alcohol | One or two drinks on some performance nights; AUDIT-C 3 |
| Mood | PHQ-9 6; item 9 scored 0 |
| Medicines | Buprenorphine with naloxone 16 mg daily; acamprosate 666 mg three times daily; thiamine; naloxone spray on hand |
Health risk assessment. Completed by the patient on paper in a private room and reviewed with her by Dr. Mayfield; kept in the confidential part of the record with her substance use treatment records. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Fair, and better than in the spring |
| Psychosocial | Supported by long-time musicians, a close friend, her counselor, and a peer recovery coach; grief for her mother still returns at times |
| Substance use | No opioid use for six weeks on buprenorphine; AUDIT-C 3 |
| Tobacco | About five cigarettes a day |
| Physical activity | Walks most days; performing is physically demanding |
| Nutrition | Irregular meals on performance days; eating more regularly at home |
| Sleep | Six to seven hours, better than at intake |
| Sexual and reproductive health | Sexually active; uses condoms; not planning a pregnancy now |
| Safety at home | Feels safe at home; no one hurts or threatens her |
| Road safety | Wears a seat belt |
| Activities of daily living | Independent |
| Oral health | No dental visit in several years |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats, or weight loss |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | No hoarseness or voice change; no dental pain |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No abdominal pain, vomiting, black stools, or yellowing of the skin; constipation settled with fiber |
| Genitourinary | Negative | No abnormal bleeding or discharge |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No skin infections or abscesses |
| Neurological | Negative | No numbness, tremor, or unsteadiness |
| Psychiatric | Negative | Mood better; PHQ-9 score 6; no thoughts of suicide or self-harm; cravings occasional and manageable |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily | One film under the tongue daily after a 4 mg first dose | Sublingual route | 1948-04-20 to 1948-04-27 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily | Two films under the tongue once daily | Sublingual route | 1948-04-27 | active | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response | Nasal route | 1948-04-20 | active | S |
| Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily | Two tablets by mouth three times daily | Oral route | 1948-04-27 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1948-04-20 to 1948-10-19 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1948-08-31 | Body height | 165 | cm | S |
| 1948-08-31 | Body weight | 68.8 | kg | S |
| 1948-08-31 | Body mass index (BMI) [Ratio] | 25.3 | kg/m2 | S |
| 1948-08-31 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1948-08-31 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1948-08-31 | Heart rate | 74 | /min | S |
| 1948-08-31 | Respiratory rate | 14 | /min | S |
| 1948-08-31 | Body temperature | 36.7 | Cel | S |
| 1948-08-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1948-08-31 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1948-08-31 | Total score [AUDIT-C] | 3 | {score} | S |
Vital signs recorded on 1948-08-31; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 68.8 kg, BMI 25.3; blood pressure 118/76 |
| Eyes | No scleral icterus |
| Mouth | Several teeth with visible decay; no abscess |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender; liver edge not palpable; no spleen enlargement |
| Skin | No spider angiomas, palmar erythema, track marks, or abscesses |
| Neurological | No tremor; gait steady |
| Psychiatric | Calm and engaged; no signs of intoxication or withdrawal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use | active | confirmed | F11.20 | S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use. |
| Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 118/76 mmHg |
| Cervical cancer screening | Ordered | No result on record; cytology with HPV testing collected today; every five years if normal |
| Chlamydia and gonorrhea screening | Ordered | Offered because of new partners in the past year; urine test today with her agreement |
| Syphilis screening | Ordered | Offered with the other sexual-health tests; drawn today |
| HIV, hepatitis C, and hepatitis B screening | Up to date | All nonreactive at intake; repeat yearly while any drug use continues |
| Pregnancy intention and contraception | Completed today | Not planning a pregnancy; uses condoms; other methods discussed and she will think about them. Buprenorphine is safe to continue in pregnancy, and she was told so |
| Intimate partner violence screening | Completed today | Negative; she feels safe at home |
| Depression screening | Completed today | PHQ-9 score 6, down from 11 six weeks ago; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 3, from 8 at intake; in treatment |
| Tobacco cessation | Declined | About five cigarettes a day; nicotine replacement and counseling offered; she is not ready and will say when she is |
| Diabetes and cholesterol screening | Not indicated | Diabetes screening begins at 35 for adults who are overweight; statin assessment begins at 40 |
| Breast and colorectal cancer screening | Not indicated | Begin at 40 and 45 |
| Hepatitis A vaccine | Due | Dose 2 at the six-month visit |
| Hepatitis B vaccine | Up to date | Two-dose series complete |
| Pneumococcal vaccine | Up to date | PCV20 at intake, recommended for adults with alcohol use disorder |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap at intake |
| Influenza and COVID-19 vaccines, this season | Due | Influenza vaccine at the six-month visit; COVID-19 vaccine discussed and she will decide then |
| HPV vaccine | Declined | Shared decision-making for adults 27 to 45; she chose not to have it |
| Dental examination | Referred | Visible decay and no dental visit in several years; dry mouth from buprenorphine discussed; dental appointment arranged |
Guideline basis: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026)
Follow-up: Six-month recovery review in seven weeks, with PEth, liver tests, blood count, the second hepatitis A dose, and the influenza vaccine. Sexual-health and cervical screening results by phone, as she asked. Dental appointment arranged. Next preventive visit in one year. Next scheduled visit 1948-10-19: six-month recovery, alcohol, liver, and mood review. [S]
Voluntary advance care planning discussion of about 16 minutes, with her consent. She named a health care agent, and a health care proxy form was completed; the agent is recorded in the confidential part of the chart and is not named here. She said that what matters most to her is her music, being treated with respect, and deciding for herself who learns about her health. She chose not to record specific treatment preferences today. The plan will be revisited yearly or after any serious illness. [S]